Elliott Portfolio Manager De La Riviere Leaves Activist Firm

Elliott Portfolio Manager De La Riviere Leaves Activist Firm

(Bloomberg) — Elliott Investment Management portfolio manager Sebastien de La Riviere has departed the activist investment firm, people with knowledge of the matter said.

De La Riviere, who worked in Elliott’s London office, left the firm earlier this month, the people said, asking not to be identified because the information is private. He helped run some of Elliott’s major health-care investments including its positions in German medical company Fresenius SE and British drugmaker GSK Plc.

De La Riviere was also involved in Elliott’s campaign at Alexion Pharmaceuticals Inc., pushing for a sale of the company before it was bought by AstraZeneca Plc for $39 billion, as well as its investment in Clinigen Group Plc, which was eventually bought by Triton Investment Management. He had been with Elliott since 2008, according to his LinkedIn profile.

Elliott’s global health-care team will continue to be overseen by senior portfolio manager Marc Steinberg, one person said.

A representative for Elliott declined to comment. De La Riviere also declined to comment.

Mark Levine, one of the most senior members of Elliott’s London office, retired late last year. His move followed other departures from Elliott’s outpost in the British capital, including Franck Tuil and James Smith, who have both gone on to start their own funds.

Elliott is one of Europe’s busiest activist investors and has waged high-profile campaigns at a number of UK FTSE 100 companies including power generator SSE Plc and homebuilder Taylor Wimpey Plc.

–With assistance from Crystal Tse and Liana Baker.

(Updates with details of Elliott team in fourth paragraph.)

More stories like this are available on bloomberg.com